Search company, investor...



Corporate Minority | Alive

Total Raised


About Eyesense

EyeSense develops an ophthalmic diagnostics system which can measure glucose levels without sampling blood. It is based on measuring the glucose in the interstitial fluid below the conjunctiva of the eye using a hand-held optical read-out device.

Headquarters Location


Missing: Eyesense's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eyesense's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eyesense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eyesense is included in 1 Expert Collection, including Diabetes.



1,899 items

Eyesense Patents

Eyesense has filed 1 patent.

The 3 most popular patent topics include:

  • Diabetes
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date


Related Topics




Diabetes, Insulin therapies, Measurement, Mechanical engineering, Fuel injection systems


Application Date


Grant Date



Related Topics

Diabetes, Insulin therapies, Measurement, Mechanical engineering, Fuel injection systems



Latest Eyesense News

VC-backed EyeSense attracts QIAGEN as strategic investor

Jul 9, 2013

Wed, 12/01/2011 - 10:16 Fund Links all funds all hedge all etf all open ended all closed ended all ucits all traditional/long all property all private equity by structure by country by city by domicile by administrator by custodian closures launches EyeSense AG, a venture capital-backed developer of novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients, has entered into a strategic partnership with QIAGEN. Capitalising on QIAGEN’s ESE fluorescence-based optical technology and on Eyesense’s glucose sensing technology, the partners intend to develop a new optical measurement technology for blood glucose monitoring in diabetes patients. QIAGEN acquired a minority equity stake in EyeSense, and attained royalty rights for future commercialisation. Both the investment and the partnership are aimed at further expanding the range of applications for the growing segment of point-of-need testing and individualised treatment of patients. Financial details have not been disclosed. EyeSense’s blood glucose monitoring (BGM) approach marks an important step forward in the diabetes field. The Company’s innovative and painless device is based on a non-invasive ophthalmic diagnostic system, and first patient studies have already yielded promising data. The ease of use, robustness, and reliability of the device will empower patients to manage their disease with confidence, and with improved comfort. EyeSense’s technology is poised to introduce a completely new way of self-diagnosis that will be applicable to other therapeutic areas as well. The Company intends to launch the new device in 2013. "The collaboration with QIAGEN is an important validation of EyeSense’s progress to date, and substantially strengthens our development efforts," says Achim Müller, CEO and co-founder of EyeSense AG. "With its leadership in innovative optical measurement systems, QIAGEN is an ideal partner to help us maximize our development and engineering know-how, take our technology to the next level, and put our advanced monitoring devices in the hands of patients at an accelerated pace. " Tags :

Eyesense Frequently Asked Questions (FAQ)

  • What is Eyesense's latest funding round?

    Eyesense's latest funding round is Corporate Minority.

  • How much did Eyesense raise?

    Eyesense raised a total of $8.3M.

  • Who are the investors of Eyesense?

    Investors of Eyesense include QIAGEN, Novartis Venture Funds, EQT Life Sciences, Private Life Biomed AG, Alstertor Private Life and 3 more.

  • Who are Eyesense's competitors?

    Competitors of Eyesense include Innara Health, Intuity Medical, Senseonics, Propeller Health, EyeIC and 13 more.

Compare Eyesense to Competitors

Third Eye Diagnostics

Third Eye Diagnostics is developing the Cerepress, a first-of-its-kind non-invasive intracranial pressure monitor that gathers information from the patient's eye. The technology is based on one issued patent, one pending patent, and two applications in progress on methods and apparatus that correlate ICP with measurements taken from the blood vessels within the eye. The Cerepress measures blood pressure in the eye's central retinal vein (CRV) which highly correlates to intracranial pressure.

Pelikan Technologies

Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr

MEC Dynamics

MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.

Neuro Diagnostic Devices

NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.

Innara Health Logo
Innara Health

Innara Health is developing new feeding technologies to measure and treat infants, children, and adults that struggle with suck, swallow, and breathe coordination. The company's flagship product is the FDA-approved NTrainer System, a neonatal technology that assesses and develops non-nutritive suck skills for newborns and infants born prematurely. Innara aims to help improve infants' time to oral feed and, in turn, decrease the length of their hospital stay. The company was founded in 2006 and is based in Olathe, Kansas.


InfraScan is developing handheld screening devices for patients in two areas: stroke and traumatic brain injury. The company's flagship product, the Infrascanner handheld imaging device, uses near infrared (NIR) light to screen for intracranial bleeding in patients with head trauma. The results of screening can be used to expedite high-risk patients for CT scanning or surgical intervention.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.